"Camptothecin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity.
Descriptor ID |
D002166
|
MeSH Number(s) |
D03.132.151
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Camptothecin".
Below are MeSH descriptors whose meaning is more specific than "Camptothecin".
This graph shows the total number of publications written about "Camptothecin" by people in this website by year, and whether "Camptothecin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2007 | 0 | 1 | 1 |
2008 | 1 | 0 | 1 |
2010 | 0 | 2 | 2 |
2013 | 0 | 1 | 1 |
2014 | 1 | 0 | 1 |
2016 | 1 | 1 | 2 |
2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Camptothecin" by people in Profiles.
-
Vranic S, Bešlija S, Gatalica Z. Targeting HER2 expression in cancer: New drugs and new indications. Bosn J Basic Med Sci. 2021 Feb 01; 21(1):1-4.
-
Duffy AG, Makarova-Rusher OV, Ulahannan SV, Rahma OE, Fioravanti S, Walker M, Abdullah S, Raffeld M, Anderson V, Abi-Jaoudeh N, Levy E, Wood BJ, Lee S, Tomita Y, Trepel JB, Steinberg SM, Revenko AS, MacLeod AR, Peer CJ, Figg WD, Greten TF. Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer. Int J Cancer. 2016 10 01; 139(7):1648-57.
-
Bonney PA, Santucci JA, Maurer AJ, Sughrue ME, McNall-Knapp RY, Battiste JD. Dramatic response to temozolomide, irinotecan, and bevacizumab for recurrent medulloblastoma with widespread osseous metastases. J Clin Neurosci. 2016 Apr; 26:161-3.
-
Mirtsching BC, George JN, Aster RH, Curtis BR. Irinotecan-induced immune thrombocytopenia. Am J Med Sci. 2014 Feb; 347(2):167-9.
-
Aguilera D, Mazewski C, Fangusaro J, MacDonald TJ, McNall-Knapp RY, Hayes LL, Kim S, Castellino RC. Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience. Childs Nerv Syst. 2013 Apr; 29(4):589-96.
-
Sun L, Morris LM, Luo J, Mackey LV, Leslie JS, Franko-Tobin LG, Fuselier JA, LePage KT, Coy DH. Application of human pancreatic carcinoid BON cells for receptor-targeted drug development. J Drug Target. 2011 Sep; 19(8):666-74.
-
McNall-Knapp RY, Williams CN, Reeves EN, Heideman RL, Meyer WH. Extended phase I evaluation of vincristine, irinotecan, temozolomide, and antibiotic in children with refractory solid tumors. Pediatr Blood Cancer. 2010 Jul 01; 54(7):909-15.
-
Wagner LM, Crews KR, Stewart CF, Rodriguez-Galindo C, McNall-Knapp RY, Albritton K, Pappo AS, Furman WL. Reducing irinotecan-associated diarrhea in children. Pediatr Blood Cancer. 2008 Feb; 50(2):201-7.
-
George RJ, Sturmoski MA, Anant S, Houchen CW. EP4 mediates PGE2 dependent cell survival through the PI3 kinase/AKT pathway. Prostaglandins Other Lipid Mediat. 2007 Feb; 83(1-2):112-20.